{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-034234","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.036531+00:00","generated_at":"2026-06-13T03:51:02.549827+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"FibroGen appoints Thane Wettig as Interim CEO; Enrique Conterno resigns","bullets":["Thane Wettig, previously Chief Commercial Officer, named Interim CEO effective July 23, 2023.","Enrique Conterno resigned as CEO and from the Board; will serve as Special Advisor through August 8, 2023.","Conterno's resignation not due to any disagreement with the company.","Wettig receives monthly $10,000 stipend on $545,000 base salary; bonus target rises to 75% of base as Interim CEO.","Conterno entered consulting agreement at $35,000 per month through September 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-034234","json":"https://secwatch.observer/filing/0000950170-23-034234.json","markdown":"https://secwatch.observer/filing/0000950170-23-034234.md","text":"https://secwatch.observer/filing/0000950170-23-034234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023034234/0000950170-23-034234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023034234/fgen-20230721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:51:02.549827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de531dc7ce","claim":"Enrique Conterno resigned as Chief Executive Officer at KYNTRA BIO, INC..","evidence_excerpt":"He succeeds Enrique Conterno, who has resigned as Chief Executive Officer and from the Board, and who will remain with the Company as Special Advisor to the Interim CEO through August 8, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023034234/0000950170-23-034234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e92fa6dcc0","claim":"Thane Wettig was appointed as Interim Chief Executive Officer at KYNTRA BIO, INC..","evidence_excerpt":"the Board of Directors (the \"Board\") has appointed Thane Wettig, age 58, to the position of Interim Chief Executive Officer (“Interim CEO”), effective July 23, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023034234/0000950170-23-034234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}